Umeclidinium bromide and vilanterol trifenatate

(Anoro Ellipta®)

Umeclidinium bromide and vilanterol trifenatate

Drug updated on 4/24/2024

Dosage FormPowder (oral Inhalation; 62.5 mcg umeclidinium and 25 mcg vilanterol)
Drug ClassAnticholinergics and long-acting beta2-adrenergic agonists
Ongoing and
Completed Studies


  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Umeclidinium bromide and vilanterol trifenatate (Anoro Ellipta) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), showing superior efficacy in lung function improvement compared to several other dual and mono-bronchodilator therapies.
  • Eleven systematic reviews/meta-analyses provide a comprehensive dataset about Anoro Ellipta's effectiveness and safety profile.
  • Among traditional agents for COPD, Aclidinium bromide/Formoterol ranks highest in terms of FEV1 improvement, followed by Umeclidinium/vilanterol. This indicates that Anoro Ellipta has significant potential in improving lung function while maintaining a good safety profile comparable to monoclonal antibodies.
  • The performance of LABA/LAMA fixed-dose combinations like Anoro Ellipta may vary depending on specific factors such as history and baseline FEV1. However, it generally shows strong efficacy against moderate or severe COPD exacerbations.
  • Network meta-analyses suggest no strong evidence of superior benefits among different LAMA/LABA combinations, including Anoro Ellipta, when reducing total exacerbations, all cause mortality after 48 weeks, indicating its comparable performance within this class.
  • Each LABA/LAMA combination, including Anoro Ellipta, has distinct profiles, highlighting the need for personalized consideration towards each drug regimen based on a study examining their efficacy/safety profiles.
  • Compared to placebo, once-daily LABA/LAMA combinations like Anoro Ellipta show clinically significant improvements in lung function and quality of life, supporting its utility up to one year for mild-moderate COPD patients.
  • The effectiveness can significantly vary based on patient history and baseline FEV1, emphasizing the importance of personalizing treatments considering individual characteristics across a wide range of severity from mild-severe airflow limitations.

Product Monograph / Prescribing Information

Document TitleYearSource
Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) Prescribing Information.2023GlaxoSmithKline, Research Triangle Park, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease.2024Frontiers in Medicine
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.2023European Journal of Clinical Pharmacology
Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. 2022Therapeutic Advances in Respiratory Disease
Efficacy and safety of LAMA/LABA fixed-dose combination therapies in chronic obstructive pulmonary disease: a systematic review of direct and indirect treatment comparisons.2022International Journal of Chronic Obstructive Pulmonary Disease
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.2022Advances in Therapy
Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.2020Respiratory Research
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations.2019Pulmonary Pharmacology and Therapeutics
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.2019Cochrane Database of Systematic Reviews
Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: a systematic review.2019The Clinical Respiratory Journal
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.2019Pulmonary Pharmacology & Therapeutics
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.2019Respiratory research
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.2019International Journal of Chronic Obstructive Pulmonary Disease

Clinical Practice Guidelines